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TIM-3 Is Expressed in Melanoma Cells and Is
Upregulated in TGF-Beta Stimulated Mast Cells
Zoltan Wiener1, Barbara Kohalmi2, Peter Pocza1, Judit Jeager2, Gergely Tolgyesi1, Sara Toth1, Eva Gorbe2,
Zoltan Papp2 and Andras Falus1,3
Many studies detect elevated numbers of mast cells in tumors, but it is still controversial whether they are
beneficial or detrimental for tumor cells. Furthermore, many tumors, such as melanomas, produce large
quantities of transforming growth factor (TGF)-b and during tumorigenesis the apoptotic and growth-inhibitory
effects of TGF-bs are lost. Based on these data we investigated the gene expression changes in TGF-bI-treated
human mast cells with DNA microarray and detected 45 differentially regulated genes, among them T-cell
immunoglobulin and mucin domain-containing protein 3 (TIM-3). As the major sources of TIM-3 ligand galectin-
9 are not tumor cells, but rather mast cells, this raises the possibility of an autocrine mechanism resulting in
local immunosuppression through the elevated TIM-3 expression by TGF-bI. Interestingly, not only melanoma
tissue sections contained TIM-3-positive mast cells, but we detected this protein also in melanoma cells.
Furthermore, TIM-3 was expressed in both WM35 and HT168-M1 melanoma cell lines at a higher level than in
isolated epidermal melanocytes, which can contribute to the lower adhering capacity of tumor cells. In
conclusion, the immunoregulatory molecule TIM-3 in TGF-b-stimulated mast cells and melanoma cells may
support the survival of this tumor type.
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INTRODUCTION
Though the function of mast cells was mostly known in
allergic immune responses and local hypersensitivity, re-
cently their importance has been shown in multiple
immunological, inflammatory, developmental, and malig-
nant processes. Human mast cells are classified based on
their protease content. Although the tryptase and chymase-
containing mast cell (MC(TC)) subtype expresses and stores
chymase, tryptase and cathepsin G and is localized in the
skin and the submucosa of gut and lung, the other basic
human mast cell type contains only tryptase and hence is
called tryptase-containing mast cell (MC(T)). This latter
subtype can be regarded as the orthologs of murine mucosal
mast cells based on their tissue localization. Interestingly,
murine and human mast cells differ in many features such as
in their differentiation program, cytokine producing capabil-
ities, or protease content. Although murine mast cells serve as
a useful model for several processes, data obtained from
these studies cannot be directly transferred to the human
system.
Transforming growth factor (TGF)-bI acts on the immune
system by multiple ways. It inhibits T-cell proliferation,
acquisition of Th cell functions, or differentiation of CD8þ
T-cells. TGF-bI also influences macrophages, B-cells,
dendritic cells, and contributes to immunosuppression and
maintenance of immunological tolerance by enhancing
conversion of CD4þCD25 T cells to CD4þCD25þ
regulatory T cells (for review see Li et al., 2006). Numerous
studies investigated the effects of TGF-bI on mast cells. This
cytokine stimulates the chemotaxis of human mast cells
(Olsson et al., 2000), influences the differentiation and
functions of isolated human intestinal mast cells (Gebhardt
et al., 2005), and downmodulates FceRI expression (Gomez
et al., 2005). After a few day long treatment TGF-bI can
induce mast cell apoptosis (Norozian et al., 2006). Further-
more, TGF-bI seems to be essential for the maturation of in
vitro-differentiated mouse mucosal mast cells (Miller et al.,
1999).
TGF-bI is thought to have a dual role in cancer
progression. The elevated incidence of chemically induced
or spontaneously occurring tumors in hemizygous or homo-
zygous Tgfb-1-null mice and the decreased risk of cancer in
TGF-bI-overexpressing animals clearly demonstrate the
tumor-suppressive effects of this cytokine (Akhurst and
Derynck, 2001; Derynck et al., 2001; Wakefield and Roberts,
2002). However, many tumors are also able to produce large
quantities of TGF-bs and during tumorigenesis apoptotic and
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growth-inhibitory effects of TGF-bs are lost. Different cancer
types, such as melanomas downregulate or modulate specific
steps of TGF-b-induced signal transduction pathways that
leads to the unresponsiveness of tumor cells to this cytokine
(Markowitz and Roberts, 1996). Melanomas are also able to
constitutively produce TGF-bI and melanoma progression
correlates with the overexpression of TGF-b growth factors
(Moretti et al., 1997). As TGF-b concentration is getting
higher, tumor cells acquire a more migratory and invasive
phenotype. TGF-b can reach this oncogenic and inva-
sion-supporting effect through local immunosuppression,
stimulation of tumor angiogenesis, or by altering stromal
environment.
Many studies investigated the immune response against
tumor cells and tried to identify key molecules that modulate
antitumor immunity. In these attempts TIM-3 may have an
outstanding role as it has been described to be Th1 cell and
CD8þ T cytotoxic 1 cell-specific protein, and Th1 cells
express TIM-3 after two or three rounds of stimulation under
Th1-polarizing conditions (Monney et al., 2002). TIM-3 has
been suggested to be a negative regulator of immune
responses with limiting the expansion of activated Th1 and
T cytotoxic 1 cell populations and was thought to be highly
specific for the above-mentioned cells. Furthermore, TIM-3
has been reported to inhibit the auto- and alloimmune
responses and to promote immunological tolerance in a
diabetes model system (Sanchez-Fueyo et al., 2003). Despite
the increasing number of published reports about TIM-3 in
the mouse, its role is still not fully understood and only a
limited amount of human data is available.
An elevated number of mast cells has been observed in or
around tumorous tissues, and these cells can belong to either
the MC(TC) or the MC(T) type depending on the local
environment (Ibaraki et al., 2005, Rojas et al., 2005), but
there is still an intensive debate if they are beneficial or
detrimental for tumor cells. In melanomas, mast cells are
thought to contribute to tumor development and progression
by causing UV-B-induced immunosuppression (Grimbaldes-
ton et al., 2004; Ch’ng et al., 2006) after degranulation and
TNF-a and histamine secretion. This latter molecule has also
been shown to enhance melanoma cell proliferation (Hegyesi
et al., 2001). Furthermore, mast cells are major sources of
potential angiogenic factors, such as fibroblast growth factor-
2 or vascular endothelial growth factor (for review see Ch’ng
et al., 2006). Usually the dominance of MC(TC) in tumors
over the MC(T) population is a predictor of good prognosis in
some types of adenocarcinomas or in renal tumors (Beil et al.,
1998; Nagata et al., 2003). Based on the high level of TGF-bs
in different tumors, such as in melanomas, we assumed that
this cytokine can cause gene expression changes influencing
interactions between mast cells and tumor cells. As our mast
cell cultures did not contain chymase either in the presence
or absence of TGF-bI, our experiments were carried out in
MC(T) cells. Microarray experiments showed that only 45
genes out of the 440,000 spotted on the chip responded to
TGF-bI treatment. The downregulation of growth differentia-
tion factor (GDF)-15 and upregulation of T-cell Ig and mucin
domain-containing protein (TIM)-3 in mast cells is indicative
for the tumor growth enhancing activity of TGF-b-treated
mast cells. Interestingly, the majority of TIM-3 ligand
galectin-9 derives not from tumor cells, but rather from mast
cells. This may result in an autocrine mechanism leading to
immunosuppression through CD80-CTLA4. TIM-3 expression
was detected not only in in vitro-differentiated, but in
melanoma-surrounding mast cells, too. Furthermore, contra-
dicting to the Th1-specificity of TIM-3, this molecule is also
expressed in melanoma cells and cell lines at a higher level
than in normal melanocytes. The elevated expression
of TIM-3 in melanoma cells may be responsible for their
lower adhering capacity and thus it can contribute to
tumorigenesis.
RESULTS
Characterization of mast cell cultures
Mast cells differentiated for 5 weeks in culture were
magnetically separated and then further cultured for an
additional 5 days in the presence or absence of TGF-bI. Real-
time PCR showed that human mast cells expressed both
components (TGF-bRI and TGF-bRII) of the functional
receptor for TGF-bI (Figure 1a). Furthermore, TGF-bI did
not influence either the cell number determined by 1-(4,5-
dimethylthiazol-2-yl)-3,5-diphenylformazan assay or cell
viability according to Trypane blue staining (data not shown).
To be sure about the effectiveness of TGF-bI-treatment, c-kit
(CD117) expression was studied by flow cytometry as
downmodulation by TGF-b of this cell surface receptor has
been published (Gebhardt et al., 2005). Figure 1b shows a
marked reduction in CD117 expression of treated mast cells.
Furthermore, no morphological alterations between un-
treated and treated human mast cells were seen with
toluidine blue staining (Figure S1).
The most characteristic difference between human mast
cell populations is their protease content. As flow cytometric
analysis showed that mast cells cultured in the presence or
absence of 2 ng/ml recombinant human TGF-bI were
uniformly positive for tryptase (Figure 2a), but they did not
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Figure 1. Cord blood-derived mast cells magnetically isolated after 5-week
culture expressed TGF-bRI and TGF-bRII and they responded to TGF-bI.
(a) TGF-bRI and TGF-bRII expression in cultured human cord blood-derived
mast cells (real-time PCR). (b) Flow cytometry with anti-human CD117 PE.
Dotted line: isotype control; simple line: untreated mast cells; bold line: mast
cells treated with 2 ng/ml TGF-bI for 5 days.
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express chymase at all (Figure 2b), we concluded that our
mast cells belonged to the MC(T) group. The presence of only
MC(T) cells in our culture is further supported by the fact that
cathepsin G, another MC(TC)-characteristic protease was not
detected by Western blotting (data not shown).
Microarray measurements
RNA samples derived from five TGF-bI-treated and control
cultures were compared by DNA microarray measurements
with one dye-swap replicate. According to our analysis,
genes upregulated in some hybridizations but downregulated
in other ones (anticorrelated genes) were not observed when
comparing the chips pairwise, which means that the
expression changes are characteristic for the treatment and
not for the individual samples. The error-weighted Pearson’s
correlation coefficients between microarrays were always
40.85 confirming that microarray measurements showed
good correlation with each other.
Surprisingly, out of the 440,000 investigated sequences
only 45 genes showed a differential expression (42.0-fold
change) at Po0.05 significance level (with Benjamini and
Hochberg false discovery rate multiple testing correction).
The up- and downregulated genes are listed in Table S2.
Gene groups based on gene ontology
Differentially expressed genes were also clustered according
to gene ontology cellular component categorization. Table S3
shows that membrane category in TGF-b-influenced gene list
is strikingly over-represented.
Validating microarray results
Expression changes of selected genes were validated either
by real-time PCR and/or at protein level. For example, the
hyaluronic acid receptor CD44 was shown to be upregulated
by TGF-b (flow cytometry: the median of fluorescence
increased by 112, 46, and 51% at three different preparates)
and there was a clear repression of the TGF-b family member
GDF-15 as validated by Western blotting (the corrected lane
density decreased by 39, 60, and 63% at three mast cell
preparates).
TIM-3 is expressed in human mast cells and is upregulated by
TGF-bI
One of the most strikingly upregulated genes after TGF-b-
treatment is hepatitis A virus cellular receptor 2 or TIM-3 that
was originally discovered as a Th1-specific protein. Both
probes fitting to exon7 (the last exon of TIM-3 gene) in Agilent
Whole Human Genome probe set showed differential
expression in our microarray experiments. According to
public databases (GeneBank, Ensembl, Swissprot) not only
the murine (Sabatos et al., 2003), but the human TIM-3 gene
also encodes an alternatively spliced form. Beside the full-
length transmembrane protein a secreted one is also
produced by using only exon1 and exon2. To investigate
the expression of the full-length messenger RNA only, real-
time PCR experiments with TaqMan probes fitting to either
exon2/3 or exon 6/7 were carried out and results confirmed
the upregulation of TIM-3 gene (Figure 3a). By using an
antibody against the extracellular domains of TIM-3 we could
find different protein levels between control and TGF-b-
treated human mast cells with Western blotting (Figure 3b)
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Figure 2. The mast cell cultures contained only MC(T) cells. Both control
and TGF-bI-treated (2 ng/ml, 5 days after 5 weeks culturing) human mast
cell cultures expressed (a) tryptase, but none of them were positive for (b)
chymase (flow cytometry). The figure shows one representative out of the
four repeated experiments. Dotted line: isotype control; simple line:
untreated mast cells; bold line: treated mast cells.
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Figure 3. TGF-bI upregulates TIM-3 in human mast cells. (a) Real-time PCR
results for TIM-3 from human mast cells with TaqMan probes fitting to either
exon6/7 (right, P¼ 0.007) or exon 2/3 (left, P¼ 0.025). Results were
normalized to glyceraldehyde-3-phosphate dehydrogenase housekeeping
(three paired samples are shown, the P-values were determined by paired
t-test). (b) TIM-3 is overexpressed in human mast cells by TGF-bI (2 ng/ml,
5 days) as detected by immunoblot (with tubulin housekeeping). C: control;
T: TGF-bI-treated samples; 1,2, and 3: different mast cell preparates.
(c) TIM-3 level is increased on the surface of human mast cells (flow
cytometry) after TGF-bI treatment (2 ng/ml, 5 days). Dotted line: isotype
control; simple line: untreated, bold line: treated mast cell preparate.
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and flow cytometry showed the increased cell surface TIM-3
expression when adding TGF-bI to the culture medium
(Figure 3c).
TIM-3 is expressed in melanoma-surrounding human mast cells
and in melanoma cells
As mast cells are often accumulated in or around melanomas
and other tumors and MC(T) cells are supposed to be
beneficial for tumor cells, TIM-3 expression was studied in
tissue sections from three different patients. Immunohisto-
chemistry revealed that both melanoma cells (Figure 4a) and
melanoma-surrounding mast cells (Figure 4b) showed a clear
positivity for TIM-3. Mast cells were identified in serial
sections with toluidine blue based on metachromatic staining
(Figure 4b). The presence of TIM-3 was also confirmed by
real-time PCR in WM35 and HT168-M1 melanoma cell lines,
and no expression difference was found either between the
cell lines or between TaqMan assays fitting to exon 6/7 or
exon 2/3 (Figure 4c). In addition, TIM-3 was detected in both
WM35 and HT168-M1 with flow cytometry (Figure 4d) and
its expression was higher than in HEMn-DP human neonatal
epidermal melanocytes (Figure 4e). Furthermore, TGF-bI did
not modify either the messenger RNA or cell surface TIM-3
level in melanoma cells (data not shown).
The TIM-3 ligand galectin-9 is expressed in human mast cells
Recently galectin-9 has been identified as the ligand for TIM-
3. To determine the potential sources of galectin-9 in
melanomas, WM35, HT168-M1 cell lines and human mast
cells were studied by real-time PCR for TIM-3 ligand
expression. Interestingly, an about B3-fold order of magni-
tude higher level of galectin-9 was detected in mast cells
compared to melanoma cell lines (Figure 5). Furthermore,
TGF-bI did not significantly modify galectin-9 expression in
mast cells (paired t-test: P40.05, data not shown).
DISCUSSION
Human CD34þ /CD117þ /CD13þ mast cell precursors
(Kirshenbaum et al., 1999) enter from bone marrow into
the blood and then migrate to peripherial tissues where they
mature under local influences of cytokines, for example of
TGF-b. As many tumors, such as melanomas are capable of
producing TGF-bI at high level, furthermore, cancer cells
become resistant to the apoptotic effect of this cytokine and
TGF-b has a clear immunosuppressive role stimulating tumor
progression and metastasis formation in later stages of cancer
development, therefore we investigated gene expression
changes of cord blood-derived, in vitro-differentiated human
mast cells after TGF-bI treatment by DNA microarray. TGF-bI
has been published to induce apoptosis both in human and
murine mast cells (Norozian et al., 2006) after some days. To
avoid the apoptotic effect, we applied a short treatment with
a low TGF-bI concentration.
The ratio of MC(T) and MC(TC) cell types during in vitro
differentiation largely depends on the exact culture condi-
tions. For example, the presence of high level stem cell factor
prefers the development of chymase-positive cells, whereas
stem cell factor at a concentration of about 50 ng/ml supports
the appearance of MC(T) cells (Ahn et al., 2000). Bagga et al.
(2004) reported that lysophosphatidic acid accelerates
human mast cell development and chymase-positive cells
were not found under such culture conditions. As MC(T)
cells are supposed to be beneficial for tumor cells, we
focused on this cell type and applied stem cell factor at
40 ng/ml with lysophosphatidic acid in our differentiation
experiments. According to flow cytometric measurements our
cultures did not contain chymase, but expressed tryptase at
high level, suggesting the appearance of only MC(T) cells.
This conclusion is further supported by the fact that cathepsin
G, another MC(TC)-specific protease could not be detected
by Western blotting.
Mast cells are capable of responding to a variety of
external stimuli. After TGF-b treatment, many differentially
regulated genes fall into the membrane category (containing
those surface molecules that influence cell–cell or cell–ex-
tracellular matrix interaction) according to gene ontology
cellular component classification. The hyaluronic acid
receptor (CD44) is well known in the human HMC-1 mast
cell line (Kruger-Krasagakes et al., 1996), in mast cells
isolated from different sources (Beil et al., 1998; Ghannadan
et al., 1998) and in cord blood-derived mast cells (Fukui
et al., 2000). The upregulation of CD44 in TGF-bI-treated
human mast cells suggests that the extracellular matrix
component hyaluronic acid may have an outstanding role
in the tissue localization of MC(T) cells in tumors, and in the
more vigorous interaction between MC(T) cells and the
extracellular matrix in cancers.
Our microarray analysis shed light on one differentially
regulated secreted molecule, GDF-15/macrophage inhibitory
cytokine-1 that is a divergent TGF-b family member. GDF-15/
macrophage inhibitory cytokine-1 inhibits proliferation of
breast (Li et al., 2000) and prostate carcinoma cells (Tan
et al., 2000). GDF-15 overexpression in HCT-116 colon
cancer cells resulted in reduced tumor growth in nude mice
(Baek et al., 2001). These data suggest that GDF-15/
macrophage inhibitory cytokine-1 may function as a tumor
suppressor at least in some cancer types. Although no
published results are available about the role and expression
of GDF-15 in melanomas, based on its downregulation in
human mast cells under the influence of TGF-bI, it is
conceivable that MC(T) cells enhance melanoma progression
partly by this mechanism.
One of our most striking findings is the presence of
hepatitis A virus cellular receptor 2 or TIM-3 in human mast
cells and its upregulation following TGF-b treatment. This
molecule was thought to be highly specific for activated Th1
and T cytotoxic 1 cells, however, further studies revealed the
expression of TIM-3 in other cells types, too. Khademi et al.
(2004) detected TIM-3 messenger RNA in natural killer
T cells, Gielen et al. (2005) proved its expression in the
resident cells of the nervous system, and in our study we
provide evidence for the presence of TIM-3 in human mast
cells. The ligand for TIM-3 has recently been identified as
galectin-9, a galactose-binding lectin that induces apoptosis
and necrosis in activated Th1 lymphocytes (Zhu et al., 2005).
Binding sites for TIM-3 (TIM3L) have been detected on the
www.jidonline.org 909
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surface of many cell types, such as on naı¨ve CD4þ T cells,
macrophages, dendritic cells (Sabatos et al., 2003), and
CD4þCD25þ regulatory T cells (Sanchez-Fueyo et al.,
2003). Anti-TIM-3 antibody decreased TIM-3 and CD80
expression on murine mast cells during acute myocarditis and
reduced Treg populations (Frisancho-Kiss et al., 2006). Based
on these known data we suggest that TGF-b-stimulated mast
cells may support the progression of tumor partly through the
higher TIM-3 expression. The higher TIM-3 level may result
in an elevated CD80 expression of human mast cells and
CD80 can interact preferentially with the inhibitory molecule
CTLA-4 leading to local immunosuppression. Indeed, pre-
vious studies have reported that blocking CD80 results in
increased CD4þ T-cell proliferation and impaired Treg
activity (Zheng et al., 2004) and inhibiting CTLA-4 function
leads to a more severe diabetes and other organ-specific
autoimmune diseases.
Interestingly, TIM-3 is expressed not only by mast cells
around melanomas, but by tumor cells in tissue sections, too.
Furthermore, human melanoma cell lines WM35 and HT168-
M1 were also positive for TIM-3. Dramatically increased
levels of the oncogenic protein SKI have been reported in
melanomas that represses the TGF-b-initialized signal-trans-
duction pathway (Medrano, 2003), therefore it was not
surprising that TGF-b did not modify the expression of TIM-3.
The presence of TIM-3 on melanoma cells can explain some
known effects of galectin-9 in tumors. According to published
studies galectin-9 induces aggregation and reduces the
adhesion of breast tumor cells to extracellular matrix proteins
(Irie et al., 2005) and similar results were published in
melanoma cells. Interestingly, the aggregation of melanoma
cells was observed at a concentration of about 108 M, but it
becomes apoptotic only at an order of magnitude higher level
(Kageshita et al., 2002). Although the extracellular galectin-9
concentration in melanomas is not known, it probable does
not reach such a high level to be able to induce apoptosis in
tumors. Furthermore, TIM-3 level is higher in melanoma cell
lines compared to normal epidermal melanocytes, which
may result in an enhanced sensitivity to galectin-9 and this
may explain the reduced adhering capacity of tumors.
To investigate the possible sources of endogenous
galectin-9 in melanomas, real-time PCR was carried out in
human mast cells and melanoma cell lines. Interestingly,
mast cells expressed galectin-9 at about 1,000 times higher
level than melanoma cell lines suggesting that the majority of
this protein derives not from tumor cells. In support of our
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Figure 4. TIM-3 is expressed both in melanoma-surrounding human mast cells and in melanoma cells. (a) Immunohistochemistry with anti-TIM3 antibody
in melanoma tissue sections. Two representatives out of three different patients. The background staining of the control slides was negligible (see Materials
and Methods). Single asterisks indicate melanoma cells. Double asterisk labels the area that is magnified in (b). Bar¼ 20 mm. (b) Asterisks mark mast
cells in serial sections. Left side: immunohistochemistry with anti-TIM3 antibody (the magnification from a part of a). Right side: mast cells show metachromatic
staining with toluidine blue. Bar¼20 mm. (c) WM35 and HT168-M1 melanoma cell lines express TIM-3 as detected by real-time PCR with TaqMan probes
fitting to either exon6/7 or exon2/3 (meanþ SEM, n¼4, the WM35 data obtained by TaqMan assay fitting to exon 2/3 were taken as 100%). (d) Both WM35
and HT168-M1 melanoma cell lines were positive for cell surface TIM-3 (flow cytometric analysis). Simple line: isotype control, bold line: anti-TIM3.
(e) Melanoma cell lines express TIM-3 at a higher level than HEMn-DP melanocytes (flow cytometry, simple line: melanocytes; bold line: WM35;
dotted line: isotype control. With HT168-M1 similar results were obtained).
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findings galectin-9 has been detected on the surface of HMC-1
human mast cell line (Chabot et al., 2002). In addition, this
protein is expressed in the cytoplasm of different melanoma
cell lines at a low level, and only a minority of cells was
positive for surface galectin-9 (Kageshita et al., 2002). Beside
mast cells, galectin-9 was found on Jurkat T-cells (Chabot
et al., 2002), furthermore, the presence of TIM-3 ligand on
regulatory T cells has been proven. Taken together, the major
source of cell surface or secreted galectin-9 does not seem to
be tumor cells, but rather mast cells and different T-cell
populations. Galectin-9 on mast cells may have an autocrine
effect and may enhance the expression of CD80 through TIM-3.
Furthermore, TGF-bI seems to regulate not the galectin-9, but
the TIM-3 level in mast cells, thus leading to immunosup-
pression.
However, the gene locus for TIM-3 encodes not only a
transmembrane protein, but a soluble isoform lacking the
transmembrane domain can be expressed by alternative
splicing both in the murine (Sabatos et al., 2003) and in the
human system (public databases), too. Initially it was
hypothesized that the soluble form binds to TIM-3 ligand
and prevents the interaction between TIM-3 and TIM-3 ligand
and thus Th1 cells continue to proliferate and to perform
effector functions (Meyers et al., 2005). However, Geng et al.
(2006) have recently found just the opposite, as soluble TIM-3
inhibited T-cell-mediated immune responses and signifi-
cantly impaired T-cell antitumor immunity in a murine
model. In our experiments we focused on the full-length
form of TIM-3 by applying TaqMan probes fitting to the full-
length TIM-3-specific exons and the soluble form was not
investigated. As soluble TIM-3 has been shown to bind to
TIM-3 ligand on CD4þ T cells and thus it can suppress the
antitumor immunity (Sabatos et al., 2003), the elevated
number of full-length TIM-3 molecules on mast cells can also
exert a similar effect.
In conclusion, we provide evidence that TGF-bI influences
the expression level of 45 genes in human MC(T) cells,
among them of CD44, GDF-15, and TIM-3. All these
expression changes in human mast cells may contribute to
tumor progression enhanced by cancer cell-derived TGF-bI.
The downregulation of GDF-15 and the upregulation of TIM-3
in mast cells may result in an immunosuppression in tumors.
Based on our findings the major sources of TIM-3 ligand
galectin-9 are not the tumor cells. Galectin-9 produced by
mast cells may act through TIM-3 in an autocrine way and the
upregulation of TIM-3 by TGF-bI may repress the local
immune response against tumor cells. Furthermore, the
higher TIM-3 expression in melanoma cells compared to
epidermal melanocytes may partly be responsible for the
reduced adhesion properties of cancer cells.
MATERIALS AND METHODS
Human mast cell cultures
Mononuclear cells from cord blood samples (taken with permission
of the National Science Ethical Committee) were separated on Ficoll-
Hypaque (Sigma, St Louis, MO) and then CD34þ stem cells were
magnetically isolated according to the manufacturer (direct CD34þ
progenitor cell isolation kit, Miltenyi Biotech, Germany). Cells were
cultured in DMEM medium (Sigma) containing 10% fetal calf serum
(Gibco BRL, Paisley, Scotland), penicillin and streptomycin (Sigma),
MEM non-essential amino acids (Sigma), 1 mM pyruvate (Sigma),
40 ng/ml stem cell factor, 20 ng/ml IL-6 (Serotec, Oxford, UK) and
3mM lysophosphatidic acid (Sigma) as it has been reported to
accelerate mast cell development (Bagga et al., 2004). Half of the
medium was replaced in every 4–6 days. After 5–6 weeks, CD117þ
mast cells were separated with mouse anti-human CD117 antibody
(Pharmingen, San Diego, CA) and magnetically labeled goat anti-
mouse IgG (Miltenyi Biotech, Germany) and further cultured for
5 days in the presence or absence of 2 ng/ml recombinant human
TGF-bI (Serotec, Oxford, UK).
Melanoma and melanocyte cell cultures
The WM35 and HT168-M1 human melanoma cell lines were
maintained in Rosewell Park Memorial Institute-1640 medium
(Sigma) supplemented with 10% fetal calf serum and 0.6 g/l
gentamycin (Chinoin Co., Budapest, Hungary). DEMn-DP neonatal
human epidermal melanocytes were purchased from Cascade
Biologics (Portland, OR) and maintained in medium provided by
the manufacturer.
Immunohistochemistry
Formalin-fixed and paraffin-embedded tissues of superficial-spread-
ing melanomas (n¼ 3; Clark Level II, T1, N0, M0) were cut and
mounted onto SuperFrost slides. Specimens were deparaffinated and
endogenous peroxidase activity was blocked by 3% H2O2 in
methanol for 30 minutes at room temperature. After rinsing in
phosphate-buffered saline (PBS), the aspecific binding sites were
blocked by normal goat serum (Dako, Denmark) for 60 minutes at
room temperature and all specimens were incubated with anti-
human TIM-3 antibody (4 mg/ml, R&D Systems, Minneapolis, MN)
diluted in PBS with 5% BSA, for 60 minutes at room temperature in a
humid chamber. As negative control, a specific goat serum was used
(Sigma). After washing in PBS, specimens were incubated with
biotinylated anti-goat antibody (Sigma) for 30 minutes at room
temperature and then washed and incubated with streptavidin/
peroxidase complex reagent (Novostain Universal Detection Kit,
Novocastra Laboratories Ltd, UK) for 20 minutes. The color was
developed by the Vector NovaRED Substrate Kit (Vector Laboratories
Inc., Burlingame, CA) and the slides were counterstained with
methyl-green (Dako, Denmark). All negative controls demonstrated
negligible background fluorescence.
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Figure 5. Galectin-9 messenger RNA level is about 1,000-fold greater in
human mast cells than in melanoma cell lines. Real-time PCR results were
normalized to glyceraldehyde-3-phosphate dehydrogenase housekeeping
(meanþ SEM, n¼ 4, Student’s t-test: Po0.001 for both mast cell WM35 and
mast cell HT108-M1 comparisons) and mast cell mean expression level was
taken as 100%.
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Toluidine blue staining
Small aliquots of mast cell cultures were cytocentrifuged, fixed in
ice-cold methanol for 10 minutes and stained with 0.1% Toluidine
blue (pH¼ 1) for 45 minutes at room temperature. Tissue sections
were stained in 0.1% Toluidine blue, pH¼ 4.
1-(4,5-Dimethylthiazol-2-yl)-3,5-diphenylformazan assay
Cells cultured in 96-well plates were treated with 1-(4,5-
dimethylthiazol-2-yl)-3,5-diphenylformazan (Sigma) at a final con-
centration of 0.5 mg/ml. After 4 hours cells were centrifuged, the cell
pellet was lysed in DMSO and the absorbance was measured at
540 nm.
Flow cytometry
In case of adherent cells, cells were first removed from tissue culture
dishes by 0.2% EDTA (Sigma). Cells were washed twice with PBS,
labeled at room temperature for 25 minutes and then analyzed by a
FACSCalibur instrument (BD Biosciences, San Jose, CA). The
following antibodies were used in our experiments: anti-human
CD117 PE, anti-human CD44 FITC (Pharmingen), goat anti-human
TIM3 (R&D Systems), mouse anti-human tryptase, mouse anti-
human chymase (Chemicon, Temecula, CA), anti-mouse IgG FITC
and anti-goat IgG FITC (Sigma). For intracellular FACS analysis, cells
were fixed in 2% paraformaldehyde for 20 minutes and permeabi-
lized by 0.1% saponin (Sigma) before labeling.
RNA isolation, quality determination, and microarray
measurements
RNA from mast cell samples was prepared by RNAEasy columns
(Qiagen, Valencia, CA), the quality and quantity of RNA was
determined with an Agilent 2100 Bioanalyzer (Agilent Technologies,
Palo Alto, CA). Only those samples were used either for microarray
or for real-time PCR experiments that gave 48.0 for RNA integrity
number, showed a clear gel image and no DNA contamination was
observed on the histogram.
200–200 ng total RNA was reverse transcribed by the Low-input
RNA Linear Amplification Kit (Agilent Technologies) and then
transcribed to either Cy3- or Cy5-labeled cRNA according to the
manufacturer. The labeled cRNA was purified (RNAEasy kit, Qiagen,
Valencia, CA), the dye content (48.0 pmol dye/mg cRNA) and the
concentration of cRNA was measured by NanoDrop ND-1000
spectrophotometer (NanoDrop Technologies, Wilmington, DE). One
microgram of Cy3 and Cy5-labeled cRNA were mixed and
hybridized to Agilent Whole Human Genome Oligonucleotide
microarrays overnight at 601C, washed by the ozone-safe saline-
sodium phosphate EDTA (SSPE) buffer method, the slides were
treated with Stabilizing and Drying Solution (Agilent Technologies)
and scanned by Agilent Microarray Scanner. All the steps were
carried out according to the manufacturer (Agilent Technologies).
Data were then normalized by the Feature Extraction software
version 7.5 with default parameter settings for oligonucleotide
microarrays and then transferred to the Rosetta Luminator (Rosetta
Biosoftware, Seattle, WA) and GeneSpring 7.3 program (Agilent
Technologies) for further statistical evaluation. To ensure that only
high-quality DNA microarray data are analyzed, some spots were
randomly selected and the Cy3- and Cy5 intensity across these spots
was analyzed. Furthermore, the distribution of up- and down-
regulated genes across the microarrays was also evaluated. In
GeneSpring the boxplot view was used for quality control and those
microarrays passed that had the median log ratio near to zero after
normalization steps recommended by Agilent Technologies for two-
color data (but the per gene step was omitted).
In our microarray experiments five biological and one technical
(dye-swap) replicates were included. Experiments were built from these
microarrays by GeneSpring and those genes were further evaluated that
showed a42.0-fold change. This gene list was then filtered for t-test P-
value (Po0.05 and the Benjamini and Hochberg false discovery rate
correction was used for multiple testing). All our microarray data have
been submitted to the GEO database (www.ncbi.nlm.nih.gov/geo/)
under the series excession number GSE4906.
Real-time PCR
1mg quality-checked RNA was reverse transcribed by 1U murine
leukemia virus reverse transcriptase (Applied Biosystems, Foster
City, CA) with random primers (Promega, Madison, WI) at 421C
for 55 minutes. Murine leukemia virus was then inactivated at
951C for 5 minutes. Real-time PCR reactions were carried out
in an ABIPrism 7000 instrument according to the manufacturer
(Applied Biosystems) with 1.5ml cDNA in each well and in 25 ml
final volume. The applied TaqMan gene expression assays are listed
in Table S1.
Immunoblotting
Cells were denatured in lysis buffer (100 mM Tris, 1% Triton X-100,
1 mM EGTA, 2.5 mM NaF, 10mg/ml leupeptin, 2 mM phenylmethyl-
sulphonyl fluoride, 10 mM Na-vanadate, 1% aprotinin) and protein
concentration was determined with the Bradford method. Protein
(15 mg) from whole-cell lysate/sample was denatured and reduced in
b-mercaptoethanol at 1001C for 5 minutes, applied to 12.5% SDS-
PAGE and then transferred to P-Immobilon (Millipore, Billerica, MA)
membrane. The full-range Rainbow (Amersham Biosciences, Piscat-
away, NJ) was used as molecular weight marker.
Blots were blocked with 10% milk powder in PBS for 1 hour
and then incubated with the primary antibody in PBS containing
1% milk powder and 0.1% Tween-20 for 2 hours at room
temperature. After excessive washings horseradish peroxidase-
conjugated secondary antibodies were applied for 45 minutes
and the signals were developed by ECL Plus Western Blotting
Detection System (Amersham Biosciences). To check the loaded
protein quantity, tubulin was measured as housekeeping. The
following antibodies were used: goat anti-human cathepsin G
(0.5 mg/ml), goat anti-human Tim3 (0.5 mg/ml), goat anti-human
GDF15 (0.5 mg/ml) (R&D Systems), rat anti-tubulin (0.5 mg/ml,
Serotec), anti-rat horseradish peroxidase (1:10,000), anti-goat horse-
radish peroxidase (1:8,000, Sigma). The density of specific lanes was
determined by ImageQuant software version 3.3 and these values
were devided by tubulin housekeeping signals (the local background
was always subtracted).
Statistical analysis
Student unpaired or paired t-tests were applied to analyze the
statistical significance of our results.
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SUPPLEMENTARY MATERIAL
Table S1. TaqMan gene expression assays used in our studies (Applied
Biosystems, Foster City, CA).
Table S2. Genes differentially regulated (42.0-fold change, Po0.05 with
Benjamini and Hochberg false discovery rate multiple testing correction)
between control and TGF-bI-treated human mast cells.
Table S3. Genes listed in Table S2 were classified according to gene ontology
cellular component.
Figure S1. Cord blood-derived mast cell praparates magnetically isolated after
5-week culture were 490% pure and TGF-bI (2 ng/ml, 5 days) did not alter
cell morphology.
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